Sign Up
OverviewAPI
Avid Bioservices, Inc. (CDMO) faces financial turmoil after revealing the misclassification of notes, leading to the restatement of its financial performance. The company grapples with challenges involving $143.8 million of exchangeable senior notes and a notable share price decline. Legal scrutiny intensifies as Hagens Berman investigates potential investor deception.

Ask a question